Giovanni Barosi focuses on Internal medicine, Myelofibrosis, Surgery, Gastroenterology and Essential thrombocythemia. His Internal medicine research integrates issues from Immunology, Oncology and Pathology. His Myelofibrosis study integrates concerns from other disciplines, such as Myeloid, Leukemia, Anemia and Transplantation.
In general Surgery study, his work on Discontinuation often relates to the realm of Nominal group technique, thereby connecting several areas of interest. Giovanni Barosi has researched Gastroenterology in several fields, including CD34, Cancer, Venous thrombosis and Histology. His Essential thrombocythemia research includes elements of Hazard ratio and Confidence interval.
Internal medicine, Myelofibrosis, Gastroenterology, Surgery and Polycythemia vera are his primary areas of study. His Internal medicine study frequently intersects with other fields, such as Oncology. His work deals with themes such as Myeloid and Anemia, which intersect with Myelofibrosis.
His research investigates the connection with Gastroenterology and areas like Adverse effect which intersect with concerns in Discontinuation. Giovanni Barosi interconnects Disease, Pediatrics, Splenectomy and Risk factor in the investigation of issues within Surgery. His study in Polycythemia vera is interdisciplinary in nature, drawing from both Phlebotomy, Hematocrit and Intensive care medicine.
Giovanni Barosi spends much of his time researching Myelofibrosis, Internal medicine, Cancer research, Bone marrow and Polycythemia vera. His Myelofibrosis study is associated with Pathology. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
The various areas that Giovanni Barosi examines in his Bone marrow study include Fibronectin, Hematopoietic stem cell transplantation and Leukemia. His studies deal with areas such as Phlebotomy and Disease as well as Polycythemia vera. His biological study spans a wide range of topics, including Thrombosis, Myeloproliferative neoplasm, Hematology and Gene expression profiling.
The scientist’s investigation covers issues in Internal medicine, Polycythemia vera, Myelofibrosis, Essential thrombocythemia and Myeloproliferative neoplasm. His Internal medicine study frequently draws connections to adjacent fields such as Oncology. Giovanni Barosi works mostly in the field of Polycythemia vera, limiting it down to topics relating to Anemia and, in certain cases, Phlebotomy.
His study looks at the relationship between Myelofibrosis and topics such as Young adult, which overlap with Mutation, IDH1, Constitutional symptoms and Predictive value of tests. His study explores the link between Essential thrombocythemia and topics such as Hematology that cross with problems in Molecular genetics, Myeloproliferative Disorders and Jak2v617f mutation. His work investigates the relationship between Disease and topics such as Surgery that intersect with problems in Quality of life.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire Harrison;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali;Heinz Gisslinger.
The New England Journal of Medicine (2012)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka.
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes.
Journal of Clinical Oncology (2011)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Alessandro M. Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;Alessandro Rambaldi.
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes;Alessandro M. Vannucchi;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali.
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy : results of a consensus process by an International Working Group
Tapani Ruutu;Giovanni Barosi;Richard J. Benjamin;Richard E. Clark.
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Tiziano Barbui;Giovanni Barosi;Alberto Grossi;Luigi Gugliotta.
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi.
Leukemia Research (2007)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Ayalew Tefferi;Giovanni Barosi;Ruben A. Mesa;Francisco Cervantes.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: